Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies

Author:

Papp Kim A.12,Haraoui Boulos3,Kumar Deepali45,Marshall John K.6,Bissonnette Robert7ORCID,Bitton Alain8,Bressler Brian910,Gooderham Melinda211,Ho Vincent9,Jamal Shahin12,Pope Janet E.1314,Steinhart A. Hillary515,Vinh Donald C.816,Wade John917

Affiliation:

1. K Papp Clinical Research, Waterloo, ON, Canada

2. Probity Medical Research, Waterloo, ON, Canada

3. Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada

4. University Health Network, Toronto, ON, Canada

5. Faculty of Medicine, University of Toronto, Toronto, ON, Canada

6. Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada

7. Innovaderm Research, Inc, Montreal, QC, Canada

8. McGill University Health Centre, Montreal, QC, Canada

9. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

10. St Paul’s Hospital, Vancouver, BC, Canada

11. Faculty of Medicine, Queen’s University, Kingston, ON, Canada

12. Vancouver Coastal Health, Vancouver, BC, Canada

13. Faculty of Medicine, University of Western Ontario, London, ON, Canada

14. St Joseph’s Health Care, London, ON, Canada

15. Mount Sinai Hospital, Toronto, ON, Canada

16. Research Institute, McGill University Health Centre, Montreal, QC, Canada

17. Vancouver General Hospital, Vancouver, BC, Canada

Abstract

Background:Patients with immune-mediated diseases on immunosuppressive therapies have more infectious episodes than healthy individuals, yet vaccination practices by physicians for this patient population remain suboptimal.Objectives:To evaluate the safety and efficacy of vaccines in individuals exposed to immunosuppressive therapies and provide evidence-based clinical practice recommendations.Methods:A literature search for vaccination safety and efficacy in patients on immunosuppressive therapies (2009-2017) was conducted. Results were assessed using the Grading of Recommendation, Assessment, Development, and Evaluation system.Results:Several immunosuppressive therapies attenuate vaccine response. Thus, vaccines should be administered before treatment whenever feasible. Inactivated vaccines can be administered without treatment discontinuation. Similarly, evidence suggests that the live zoster vaccine is safe and effective while on select immunosuppressive therapy, although use of the subunit vaccine is preferred. Caution regarding other live vaccines is warranted. Drug pharmacokinetics, duration of vaccine-induced viremia, and immune response kinetics should be considered to determine appropriate timing of vaccination and treatment (re)initiation. Infants exposed to immunosuppressive therapies through breastmilk can usually be immunized according to local guidelines. Intrauterine exposure to immunosuppressive agents is not a contraindication for inactivated vaccines. Live attenuated vaccines scheduled for infants and children ⩾12 months of age, including measles, mumps, rubella, and varicella, can be safely administered as sufficient time has elapsed for drug clearance.Conclusions:Immunosuppressive agents may attenuate vaccine responses, but protective benefit is generally maintained. While these recommendations are evidence based, they do not replace clinical judgment, and decisions regarding vaccination must carefully assess the risks, benefits, and circumstances of individual patients.

Funder

Dermatology Association of Ontario

Publisher

SAGE Publications

Subject

Dermatology,Surgery

Cited by 91 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus;The Journal of Pediatrics: Clinical Practice;2024-12

2. Treatment of Behçet Uveitis in Türkiye;Turkish Journal of Ophthalmology;2024-08-29

3. Pemphigus and Pregnancy;Indian Dermatology Online Journal;2024-05-20

4. Methotrexate and immunogenicity of vaccines in patients with rheumatic diseases;Rheumatology Science and Practice;2024-04-29

5. Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis;Journal of Clinical Medicine;2023-12-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3